CD8A and ovarian cancer: Our results follow and confirm the original observation by our group [6] in which a significant reduction of Tregs and an increase in the proportion and function of effector CD8 T cells were found in an end-of-life ovarian cancer patient treated with low-dose intraperitoneal bevacizumab for malignant ascites.